ARMS‐qPCR‐Based Detection of BRAF and TERT Promoter Mutations: A Cost‐Effective Strategy for Molecular Diagnosis of Papillary Thyroid Carcinoma
International Journal of Endocrinology · 2026-01 · 2026 (1)
DOI: 10.1155/ije/8104155 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Endocrinology, online erschienen am 15.05.2026. Verfasst von Yuanyuan Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Center, Xi'an Bioreal-Coming BioMed Center Co., Ltd., Xi'an, Shaanxi, China. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to establish a rapid and sensitive method for detecting BRAF V600E, TERT C228T, and TERT C250T mutations using amplification‐refractory mutation system‐quantitative PCR (ARMS‐qPCR) combined with TaqMan probes. We systematically evaluated the assay’s accuracy, sensitivity, repeatability, and specificity in the laboratory and assessed detection performance in clinical samples, in which a total of 40 formalin‐fixed paraffin‐embedded samples (34 papillary thyroid carcinoma [PTC] tissues and 6 normal tissues) were analyzed by ARMS‐qPCR, commercial kits, and Sanger sequencing. In the laboratory, the ARMS‐qPCR assay exhibited superior performance of accuracy, sensitivity, repeatability, and specificity. In clinical samples, ARMS‐qPCR detected BRAF V600E mutation in 82.35% (28/34) and TERT C228T in 5.9% (2/34), which the commercial kit performed equally, while Sanger sequencing identified BRAF V600E in 50% (17/34) and TERT C228T in 2.9% (1/34). Simultaneously, neither method detected TERT C250T mutations. The ARMS‐qPCR method demonstrated significantly higher sensitivity than Sanger sequencing, along with advantages of rapid turnaround (2‐3 h), cost‐effectiveness, and broad applicability. These findings highlight ARMS‐qPCR as a robust, sensitive, and efficient approach for detecting BRAF and TERT promoter mutations in PTCs, offering substantial potential for clinical molecular diagnostics and personalized management of thyroid cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research and Development Center, Xi'an Bioreal-Coming BioMed Center Co., Ltd., Xi'an, Shaanxi, China.
- Department of Pathology, The Second People's Hospital of Dingxi, Dingxi, Gansu, China.
ORCID-Profile: Yuanyuan Jia, Yajun Zhang, Dandan Sun, Jiabao Yang, Mengshi Zhou, Min Gao, Rui Li
Zitieren
APA
Jia, Y., Zhang, Y., Sun, D., Yang, J., Zhou, M., Gao, M., & Li, R. (2026). ARMS‐qPCR‐Based Detection of BRAF and TERT Promoter Mutations: A Cost‐Effective Strategy for Molecular Diagnosis of Papillary Thyroid Carcinoma. International Journal of Endocrinology, 2026(1). https://doi.org/10.1155/ije/8104155
Vancouver
Jia Y, Zhang Y, Sun D, Yang J, Zhou M, Gao M, et al. ARMS‐qPCR‐Based Detection of BRAF and TERT Promoter Mutations: A Cost‐Effective Strategy for Molecular Diagnosis of Papillary Thyroid Carcinoma. International Journal of Endocrinology. 2026;2026(1). doi:10.1155/ije/8104155
BibTeX
@article{Jia2026,
author = {Jia, Yuanyuan and Zhang, Yajun and Sun, Dandan and Yang, Jiabao and Zhou, Mengshi and Gao, Min and Li, Rui},
title = {ARMS‐qPCR‐Based Detection of BRAF and TERT Promoter Mutations: A Cost‐Effective Strategy for Molecular Diagnosis of Papillary Thyroid Carcinoma},
journal = {International Journal of Endocrinology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ije/8104155}
}
EUVIMED